Trial NCT04566770
Publication Zhu F(1), Clin Infect Dis, 2021
Primary outcome on the report: 1. Incidence of adverse reactions within 14 days after each vaccination. 2. GMT of RBD-specific ELISA antibodies on day 28 after boost vaccination. 3. GMT of pseudovirus neutralising antibodies on day 28 after boost vaccination.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.